For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP39

2219

Dr.Manjula Krishna
Membership No Author Name Email Mobile
2219 Dr.Manjula Krishna drmanjula_k2007@yahoo.com 9980160322
Medical Retina

Ocular Effects of GLP-1 Receptor Agonists: Benefits, Risks & Clinical Guidance

Purpose: To evaluate the ocular benefits and risks of GLP-1 receptor agonists (GLP-1 RAs) in diabetic patients. Methods: Literature review of 61 articles (2016-2026) from PubMed including meta-analyses, population studies, and case reports analyzing GLP-1 RA ocular effects. Results: GLP-1 RAs demonstrated protective effects: reduced diabetic retinopathy progression (8 studies, strong evidence), decreased neovascular AMD risk, glaucoma neuroprotection with IOP reduction, and improved ocular surface parameters. Mechanisms include anti-inflammatory, antioxidant, and neuroprotective pathways via retinal GLP-1 receptors. Risks identified: NAION association (6 case reports), rare vision impairment signals in FDA data. Semaglutide was most studied (12 articles). Conclusion: GLP-1 RAs offer significant ocular benefits for diabetic patients while requiring NAION vigilance. Baseline eye exams and symptom monitoring are recommended before and during therapy.

No Co-Author Selected